Improving Venous Thromboembolism Prophylaxis
|ClinicalTrials.gov Identifier: NCT01304108|
Recruitment Status : Completed
First Posted : February 25, 2011
Last Update Posted : February 25, 2011
|Condition or disease||Intervention/treatment||Phase|
|Venous Thromboembolism Delivery of Health Care Quality Improvement||Other: VTE-P Tollgate Other: BLAZE Pop up Other: Usual Care||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||3000 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Health Services Research|
|Official Title:||Spreading and Improving DVT Prophylaxis at Mayo Clinic (DVT-P-Spread)|
|Study Start Date :||January 2009|
|Primary Completion Date :||May 2010|
|Study Completion Date :||May 2010|
Experimental: Order Set
Insertion of VTE-P Order Set "tollgate" in all active admission and transfer orders.
Other: VTE-P Tollgate
Add VTE-P tollgate order set that requires a decision regarding VTE-P for every patient admitted or transferred in our hospital system
Experimental: Clinical Decision Support Pop-up
Deploy rules-based pop-up that reminds ordering clinicians when patients do not have an active VTE-P plan.
Other: BLAZE Pop up
Develop and deploy a rules-based popup that reminds prescribers interfacing with the orders system when a patient does not have an active VTE-P plan.
Active Comparator: Usual Care
Usual care, without the experimental additions
Other: Usual Care
No addition to the baseline system for care
- % of in patients with an appropriate VTE prophylaxis plan [ Time Frame: Baseline to 1 month ]The investigators will measure the number of patients in a statistically valid random sample of hospitalized patients who have a VTE-prophylaxis plan consistent with current recommendations.
- Clinically significant complications of VTE-P anticoagulant therapy [ Time Frame: baseline to 1 month ]The investigators will determine the rate of bleeding complications in inpatients using a statistically valid random sample of hospitalized patients. The investigators will also determine the rate of procedure delays due to VTE-P related anticoagulation.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01304108
|United States, Minnesota|
|Mayo Clinic in Rochester|
|Rochester, Minnesota, United States, 55905|
|Principal Investigator:||Timothy Morgenthaler, MD||Mayo Clinic|